Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Go back to Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease| Diversified Corporate Resources, Inc. (NASDAQ: IRD) | Delayed: 4.67 +0.07 (1.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.60 | 52 Week High | $0.02 | |||
| Open | $4.53 | 52 Week Low | $0.02 | |||
| Day High | $4.80 | P/E | N/A | |||
| Day Low | $4.40 | EPS | $0.00 | |||
| Volume | 2,239,734 | |||||
